{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:19:40Z","timestamp":1787019580919,"version":"build-2736575974"},"reference-count":39,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multiple myeloma (MM), a neoplasm of plasma cells, is the second most common hematologic malignancy. With treatment advances, patients are living longer. However, the disease remains incurable. MM patients are started on a combination of antineoplastic agents with the aim of achieving disease remission. However, at some point patients will experience a relapse requiring another type of therapy. The attrition rate is high, and the periods of remission with each line of therapy become shorter as MM becomes biologically more complex and refractory to treatment. In other words, the initial induction strategy could have a significant impact on the patient's disease trajectory because this will likely be the best and most durable response for the patient. The upfront regimen for a new MM patient is determined based on disease-specific factors such as biology (cytogenetics, circulating plasma cells, extramedullary disease) as well as patient-related factors such as performance status, organ impairment, comorbidities, and fitness status. For patients considered fit, the treatment goal is to achieve maximum therapeutic efficacy to obtain the best disease response. The definition of fitness varies for each trial, and it is a subjective assessment by the provider. It does not necessarily correlate with whether a patient is considered transplant eligible. Patients may choose to defer transplant or may not be offered a transplant based on age cutoff geographically despite being fit. These patients are included in studies for transplant-ineligible patients. In this review, we evaluate the best induction regimen for MM patients fit for treatment.<\/jats:p>","DOI":"10.1182\/hematology.2025000731","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:08:57Z","timestamp":1764943737000},"page":"405-411","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["What is the best induction for myeloma for the fit patient?"],"prefix":"10.1182","volume":"2025","author":[{"given":"Nishi Nilesh","family":"Shah","sequence":"first","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"2025120616335457500_hem2025000731C1","unstructured":"US Food and Drug Administration ODAC Committee YouTube page. Accessed 29May2025. https:\/\/www.youtube.com\/watch?v=pooME9gMaL0. 2024."},{"issue":"12","key":"2025120616335457500_hem2025000731C2","volume":"8","author":"ClonoSEQ cleared for residual cancer testing","year":"2018","journal-title":"Cancer Discov"},{"issue":"6","key":"2025120616335457500_hem2025000731C3","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024027620","article-title":"Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results","volume":"146","author":"Corre","year":"2025","journal-title":"Blood"},{"issue":"12","key":"2025120616335457500_hem2025000731C4","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1002\/ajh.27484","article-title":"FDA IDE validation of multiple myeloma MRD test by flow cytometry","volume":"99","author":"Jevremovic","year":"2024","journal-title":"Am J Hematol"},{"issue":"1","key":"2025120616335457500_hem2025000731C5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood.2024026230","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial","volume":"146","author":"Perrot","year":"2025","journal-title":"Blood"},{"issue":"1","key":"2025120616335457500_hem2025000731C6","first-page":"2000","article-title":"MRD-guided sequential therapy for deep response in newly diagnosed multiple myeloma (NDMM)- Master-2 trial","volume":"144","author":"Dhakal","year":"2024","journal-title":"Blood"},{"issue":"16","key":"2025120616335457500_hem2025000731C7","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1200\/JCO.2025.43.16_suppl.7503","article-title":"Randomized, multi-center study of carfilzomib, lenalidomide, and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM): the ADVANCE clinical trial","volume":"43","author":"Landgren","year":"2025","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"2025120616335457500_hem2025000731C8","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"14","key":"2025120616335457500_hem2025000731C9","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"25","key":"2025120616335457500_hem2025000731C10","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J Clin Oncol"},{"issue":"17","key":"2025120616335457500_hem2025000731C11","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"2025120616335457500_hem2025000731C12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2023-177546","article-title":"Results of the phase III randomized ISKIA trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients","volume":"142","author":"Gay","year":"2023","journal-title":"Blood"},{"issue":"23","key":"2025120616335457500_hem2025000731C13","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.22.02567","article-title":"Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma","volume":"41","author":"Kaiser","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10192","key":"2025120616335457500_hem2025000731C14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"2025120616335457500_hem2025000731C15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma","volume":"42","author":"Leypoldt","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"2025120616335457500_hem2025000731C16","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat Med"},{"issue":"6","key":"2025120616335457500_hem2025000731C17","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jamaoncol.2021.0611","article-title":"Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial","volume":"7","author":"Landgren","year":"2021","journal-title":"JAMA Oncol"},{"issue":"16","key":"2025120616335457500_hem2025000731C18","doi-asserted-by":"crossref","first-page":"8000","DOI":"10.1200\/JCO.2023.41.16_suppl.8000","article-title":"Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: post-induction response and MRD results from an open-label randomized phase 3 study","volume":"41","author":"Knop","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025120616335457500_hem2025000731C19","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S2352-3026(24)00070-X","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial","volume":"11","author":"O'Donnell","year":"2024","journal-title":"Lancet Haematol"},{"issue":"4","key":"2025120616335457500_hem2025000731C20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"16","key":"2025120616335457500_hem2025000731C21","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2022.40.16_suppl.8002","article-title":"Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk, transplant-eligible patients with newly diagnosed myeloma: results of the phase 2 study IFM 2018-04","volume":"40","author":"Touzeau","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025120616335457500_hem2025000731C22","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"2025120616335457500_hem2025000731C23","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3026(20)30354-9","article-title":"Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial","volume":"8","author":"Usmani","year":"2021","journal-title":"Lancet Haematol"},{"issue":"8","key":"2025120616335457500_hem2025000731C24","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2025120616335457500_hem2025000731C25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41408-024-01045-3","article-title":"Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant","volume":"14","author":"Derman","year":"2024","journal-title":"Blood Cancer J"},{"issue":"11","key":"2025120616335457500_hem2025000731C26","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1200\/JCO-24-02266","article-title":"Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 trial","volume":"43","author":"Mai","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16","key":"2025120616335457500_hem2025000731C27","doi-asserted-by":"crossref","first-page":"8057","DOI":"10.1200\/JCO.2023.41.16_suppl.8057","article-title":"A phase 2 evaluation of daratumumab-based induction therapy in patients with multiple myeloma with severe renal insufficiency","volume":"41","author":"Harvey","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025120616335457500_hem2025000731C28","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/leu.2013.216","article-title":"The BCL-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma","volume":"28","author":"Touzeau","year":"2014","journal-title":"Leukemia"},{"key":"2025120616335457500_hem2025000731C29","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1182\/blood-2018-99-119051","article-title":"Outcomes of myeloma patients with t(11;14) receiving lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy","volume":"132","author":"Kaufman","year":"2018","journal-title":"Blood"},{"issue":"24","key":"2025120616335457500_hem2025000731C30","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International Myeloma Society\/ International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma","volume":"43","author":"Avet-Loiseau","year":"2025","journal-title":"J Clin Oncol"},{"issue":"20","key":"2025120616335457500_hem2025000731C31","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood.2023023597","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma","volume":"143","author":"Touzeau","year":"2024","journal-title":"Blood"},{"key":"2025120616335457500_hem2025000731C32","unstructured":"Phase 1\/2 trial of iberdomide in combination with daratumumab, bortezomib and dexamethasone in patients with newly diagnosed multiple myeloma (IDEAL). Accessed 29May2025. https:\/\/clinicaltrials.gov\/study\/NCT05392946. 2022."},{"key":"2025120616335457500_hem2025000731C33","unstructured":"GEM21menos65. A phase III trial for NDMM patients who are candidates for ASCT comparing extended VRD plus early rescue intervention vs isatuximab-VRD vs isatuximab-V-iberdomide-D. Accessed 29May2025. https:\/\/clinicaltrials.gov\/study\/NCT05558319. 2022."},{"key":"2025120616335457500_hem2025000731C34","unstructured":"A phase 3, randomized, open-label study of belantamab mafodotin administered in combination with lenalidomide and dexamethasone (BRd) versus daratumumab, lenalidomide, and dexamethasone (DRd) in participants with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (TI-NDMM). Accessed 29May2025. https:\/\/clinicaltrials.gov\/study\/NCT06679101. 2024."},{"key":"2025120616335457500_hem2025000731C35","unstructured":"Low-dose teclistamab as consolidation in the first-line treatment of patients with newly diagnosed multiple myeloma. Accessed 29 May 2025. https:\/\/clinicaltrials.gov\/study\/NCT06758375. 2024."},{"issue":"1","key":"2025120616335457500_hem2025000731C36","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1182\/blood-2024-199773","article-title":"Talquetamab, a GPRC5D\u200a\u2009\u00d7\u2009\u200aCD3 bispecific antibody, in combination with daratumumab and lenalidomide in patients with newly diagnosed multiple myeloma: safety and efficacy results from the phase 1b monumental-2 study","volume":"144","author":"Nooka","year":"2024","journal-title":"Blood"},{"key":"2025120616335457500_hem2025000731C37","unstructured":"Selinexor (ATG-010) plus bortezomib, lenalidomide and dexamethasone (XVRd) in high risk newly diagnosed multiple myeloma. Accessed 29May2025. https:\/\/clinicaltrials.gov\/study\/NCT05422027. 2022."},{"key":"2025120616335457500_hem2025000731C38","unstructured":"MRD-guided sequential therapy for deep response in newly diagnosed multiple myeloma\u2014MASTER-2 trial. Accessed 29May2025. clinicaltrials.gov\/study\/NCT05231629. 2022."},{"issue":"suppl 1","key":"2025120616335457500_hem2025000731C39","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1182\/blood-2022-157021","article-title":"DVRd followed by ciltacabtagene autoleucel versus DVRd followed by ASCT in patients with newly diagnosed multiple myeloma who are transplant eligible: a randomized phase 3 study (EMagine\/CARTITUDE-6)","volume":"140","author":"Boccadoro","year":"2022","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/405\/2470002\/405kaufman.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/405\/2470002\/405kaufman.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:34:01Z","timestamp":1765056841000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2025\/1\/405\/556897\/What-is-the-best-induction-for-myeloma-for-the-fit"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,5]]},"published-print":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2025000731","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,5]]},"published":{"date-parts":[[2025,12,5]]}}}